The Debate is Over: Continue Anti-Tumor Necrosis Factor Therapy Throughout Pregnancy

Eric J. Mao, Uma Mahadevan

Research output: Contribution to journalEditorial

2 Scopus citations


Data in support of the safety of biologic use during pregnancy continues to grow. Utilizing a national French database with linkage between mothers and children, Luu et al. demonstrated that anti-tumor necrosis factor (anti-TNF) therapy exposure did not increase infection risk in children, though the mothers had higher rates of infection. Stopping therapy prior to 24 weeks gestation led to a higher rate of disease flares in the mother with no benefit to the infant compared to continued therapy.

Original languageEnglish (US)
Pages (from-to)1590-1591
Number of pages2
JournalAmerican Journal of Gastroenterology
Issue number11
StatePublished - Nov 1 2018


ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Cite this